Bulgaria will rely on the speed and efficiency of its domestic authorisation procedures for innovative drug therapies to attract the interest of pharma companies to its small domestic market, the Ministry of Health told Euractiv.
The EU’s increasing reliance on pharmaceutical production from non-EU countries, particularly India and China, has raised serious concerns, newly elected Czech MEP Ondลej Dostรกl (NI) said in an interview with Euractiv Czechia.
SNEAK PEEK โ EU health policy is now split across multiple departments, and MEPs arenโt happy. โ Sort your own house out first: MEPs question Hungarian health secretary over presidency plans and countryโs health commissioner role. โ Spend less on defense and more on health, WHO chief Tedros told world leaders at the United Nations [โฆ]
Greater collaboration between industry, government, policymakers and the NHS will be critical for treatment options in the UK to match the pace of scientific innovation. What is our route to achieving timely patient access across the country like our European neighbours?
Proposed European pharmaceutical reforms aim to tackle, amongst others, healthcare access inequalities amongst Member States. However, some of the proposed changes may limit innovation and negatively impact patient access to medicines, highlighting the…
Some experts lament the lack of bolder commitments in farming.
Despite calls to step up efforts, investment in antimicrobial resistance is still insufficient.
A staggering percentage of people in the Netherlands use herbal products in combination with other medications, without first discussing it with their healthcare professionals, the Dutch Medicines Evaluation Board (MEB) told Euractiv.
Irish pharmacists are set to gain new prescribing roles following an expert report recommending they should prescribe for a range of common conditions. Irelandโs leading pharmacy union is supportive, conditional on the resolution of a pay dispute.
Talks around the ‘incentives-cluster’ within the EU’s pharma legislation remain wide open, with Athens supporting the so-called ‘delinked option’, says Aris Angelis, Secretary General for Strategic Planning of the Greek health ministry.
From creating an EU-wide money market to protecting kids online, POLITICO looks at what lies ahead for lawmakers.
Access to novel medicines continues to vary widely across EU member states. Though health remains mostly a national competence, a new Euractiv cross-country report shows patients in each country face unequal challenges when accessing new therapies.
The countryโs Council stint will be marked by political change in Brussels following the EU election.
A new wave of radioligand therapies is approaching. With healthcare systems and policymakers ill-equipped to handle the change, Belgium is launching an action plan.
Concerns have been raised about the relative effectiveness of an increasing number of new medicines at the time of their market authorisation, a spokesperson for outgoing Dutch Medical Care Minister Pia Dijkstra told Euractiv.
Bulgaria continues to experience serious medicine supply problems, leading caretaker Health Minister Galya Kondeva to extend the export ban on antibiotics for children, insulin and blood sugar-lowering drugs until mid-July.
A coalition of six EU member states has warned against some countries’ massive stockpiling of medicines, warning that such practices might cause significant shortages in other parts of the European Union.
In January 2025 the EU HTA Regulation will become reality. Letโs work together to ensure it facilitates faster patient access to new cancer treatments.
Lower drug pricing does not follow from an expansion of innovative medicine indications, according to Dutch researchers. They claim pharma companies often fail to pass on their financial gain to patients and health services.
Dreaming of a third Parliamentary mandate, Tiemo Wรถlken, 12th on the list of the German Social Democratic Party (SPD), reflects on his tenure in the European Parliament in an interview with Euractiv.
Bulgariaโs updated position paper on the revision of the EU’s pharmaceutical legislation underlines the importance of national competence and focuses on access to new medicines for citizens of poorer countries.
Polish medical innovation has seen improvements, yet significant challenges remain, according to the latest Access GAP data, with access to innovative therapies and diagnostics increasing.
In Czechia, new data shows over 16,000 patients have been included in the research efforts for new drugs and vaccines, with clinical trials most frequently focusing on oncology and immunology.
Swedish doctors fear Swedish patients may have to pay out-of-pocket for a treatment that targets a genetic cause of the neurodegenerative disease ALS. European authorities will decide this spring whether the drug can be marketed in Europe.
Eighty-five percent of Poles believe that drug prices in the country are high, according to a survey conducted by Ariadna, the Nationwide Research Panel for Health Market. Despite this perception, the prices of reimbursed drugs in Polish pharmacies are…
The HTA Regulation was intended to streamline how the value of medicines is assessed, but by overburdening the process, it risks making patients wait for new therapies. Now is the time to come together to ensure we can realise the potential of the EU H…
Bulgaria remains the only country in the EU where the death rate from oncological diseases continues to rise. Patients face financial and organisational difficulties in accessing treatment, even though public funding has more than doubled in the past f…
The Belgian Presidency is gearing up to tackle the escalating issue of medicine shortages across Europe. Experts call for enhanced collaboration, solidarity, and transparency to combat this crisis effectively.
Hungary’s Minister of State for Health, Pรฉter Takรกcs, has said a new approach is needed to allow Hungary to choose medicines better suited to the national health budget.
Patients with rare diseases are clear beneficiaries of the European Parliamentโs vote on the EU Pharma Package, says Belgian MEP Frรฉdรฉrique Ries. The revised package will also embed a European solidarity mechanism.
In early 2025, Europe will implement a uniform, pan-EU framework under the new Health Technology Assessment Regulation (HTAR), addressing disparities in evaluating the clinical value of pharmaceuticals and medical devices.
The EFPIA HTA Working Group’s Inka Heikkinen and James Ryan spoke with Euractivโs Nicole Verbeeck, giving insights on moving towards a robust HTA system โ one that serves patients, industry and progress in Europe or member states.
People living with rare diseases in Slovakia are facing a high risk of impoverishment and discrimination, while Slovak access to medicines continues to rank among the worst in the EU.
EU pharmaceutical legislation is undergoing a major reform which is an opportunity to increase peopleโs access to medicines, but worryingly some right-leaning political groups want to give even more power to the pharma industry, writes Monique Goyens, …
The first advanced drug therapies centre for children in the Nordics is opening its doors in Sweden, and it is welcoming patients from neighbouring countries.
Patients need access to medicines, equally and unobstructed across the European Union. This was the message echoing throughout the EU Pharmaceutical Roundtable, organised by MEP Adam Jarubas (EPP) at the European Parliament.
Innovation only matters if it reaches patients.
Swedenโs government wants to strike a balance between ensuring access to medicines for all patients and creating the best conditions for the research and development of new drugs, according to statements made during a recent public hearing.
A wave of concerning policies around the globe that are currently being implemented or are under discussion will, if the trend continues, have a profoundly negative impact on patients.
The ongoing review of the EU Pharmaceutical Legislation is looking at recalibrating IP incentives. Intellectual Property fuels medical innovations from the research bench to the patient’s bedside.
Clear contradictions, confusing communication and questions about the involvement of a major pharmaceutical lobby group in the publishing and unpublishing of a medical study filled the room at the latest meeting of the Panel for the Future of Science a…
